An update from Adicet Bio ( (ACET) ) is now available.
Adicet Bio, Inc. announced the commencement of patient enrollment for the Phase 1 clinical trial of ADI-001, a promising new treatment for autoimmune diseases such as lupus nephritis, systemic lupus erythematosus, systemic sclerosis, and ANCA associated vasculitis. With clinical sites now activated, the company aims to expand patient enrollment across additional conditions by the end of the year and is set to release preliminary data in the first half of 2025. This follows the FDA’s Fast Track Designation for ADI-001, highlighting its potential as a significant advancement in autoimmune disease therapy.
Find detailed analytics on ACET stock on TipRanks’ Stock Analysis page.
